(Newswire.net — November 18, 2022) —
According to a new research study by Global Insight Services (GIS), the companion diagnostics market is expected to grow rapidly over the next 10 years to reach a value of more than the US $18.0 billion by 2031.
Companion diagnostics is a medical device used along with therapeutic drugs to analyze the effect & applicability of drugs on a specific human body. Companion diagnostics are developed along with drugs for selecting or excluding groups of patients based on the characteristics of which they respond to the therapy. This device helps the healthcare professional to analyze whether a particular treatment is beneficial to the patient.
Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10261/
Global Companion Diagnostics Market: Key Drivers
The key factor such as the growing requirement for targeted medicine is boosting the growth of the market. With advances in genetic sequencing and genomics, it is now extensively believed that drugs can show varying outcomes in different individuals. A better understanding of the genetic characteristics or biomarkers of an individual can promote the practice of administering the right drug, at the right time, at the right dose, for the right person. Pharmaceutical and biopharmaceutical companies are regularly attempting to implement patient-selection diagnostic frameworks in the earlier stages of drug development to provide targeted therapies to the right candidate. This further boosted the growth of the companion diagnostics market.
Similarly, the increasing demand for next-generation sequencing is also refueling the market during the forecast period. NGS-based companion diagnostic target to unlock molecular information from each patient’s tumor genome to guide treatment decisions for cancer therapies. Next-generation sequencing detects multiple biomarkers for multiple drug therapies in a shorter time frame as compared to other sequencing techniques. The use of NGS panels for biomarker measurement in one test has the potential to help in the treatment of various types of cancers. The various technological advancements in NGS also provide market players with an immediate competitive edge over players providing other technologies such as PCR, ICH, and ISH. Owing to that, major market players are focusing on developing companion diagnostic products based on NGS.
Report Findings
The assay, kits & reagents accounted for the largest share of the companion diagnostics market in 2021
The factors such as the availability of a wide range of products coupled with the increasing use of assays and kits in different therapeutic areas are boosting the growth of the market.
The PCR segment is likely to dominate the market during the forecast period
Ease of use coupled with the widespread availability of PCR kits & reagents in companion diagnostic testing and growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes are some factors boosting the market growth.
The cancer segment is likely to dominate the market during the forecast period
Factors such as the growing role of companion diagnostics in the personalized medicine treatment for cancer coupled with the increasing utility of biomarkers in the diagnosis of cancer are boosting the market growth.
The pharmaceutical & biopharmaceutical companies segment is likely to dominate the market during the forecast period
The key factors such as the growing use of companion diagnostics owing to their increasing prominence in drug development coupled with the increasing importance of companion diagnostic biomarkers are boosting the market growth.
Competitive Landscape
The key players of the companion diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).